News

At the end of February, to kick off March as Bleeding Disorders Awareness Month, GLHF joined more than 400 members of the…

On March 4, GLHF headed to Madison for our annual Wisconsin Legislative Day – a chance to share with lawmakers the true…

Patients on home therapy receive regular shipments of clotting factor concentrate (CFC) or non-factor replacement therapy (e.g., emicizumab-kxwh) from their pharmacy providers,…

On March 27th, experts from NHF answered your questions regarding changes in insurance in our townhall webinar: Insurance: Coping During COVID-19.  …

The National Hemophilia Foundation’s (NHF’s) Medical and Scientific Advisory Council (MASAC) issued four new documents, which were adopted by NHF’s Board of…

DRINK LOCAL. GIVE LOCAL. When GLHF started Milwaukee’s Best Bloody eight years ago, we were looking for a fresh way to raise…

On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community. You can watch the webinar in…

Dear GLHF Community Members, We are thinking of you every day. As we navigate this current health crisis together, our primary concern is,…

I know many of you are overwhelmed with often-conflicting information on the COVID-19 virus. As a doctor and researcher, the health of…

As a community, we know how important it is for people with bleeding disorders to maintain comprehensive health insurance. Amid the uncertainty…

Novo Nordisk recently announced that they have “paused” three clinical trials for their investigational subcutaneous therapy concizumab. The therapy is developed using…

NHF will be posting all communications from pharmaceutical companies regarding any potential affects that the COVID-19 pandemic could have on the manufacture…

As we continue to monitor the COVID-19 outbreak in the US and around the world, we understand the uncertainty that it may…

As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U….

The greatest asset at NHF is the community we serve – our family of staff and volunteers. We are aware of the…

The Centers for Disease Control and Prevention (CDC) is responding to the rapidly evolving situation of the outbreak of respiratory disease (COVID-19)…

Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S….

The Partners in Bleeding Disorders Education Program has announced the launch a new version of “Understanding Hemophilia,” a six-part online learning activity for clinicians…

It is critical that an individual with a bleeding disorder who presents in an emergency department (ED) be triaged and administered care…

The National Hemophilia Foundation (NHF) has been monitoring the latest information on the current coronavirus (2019-nCoV) as it pertains to the bleeding…

Novo Nordisk has announced the launch of ESPEROCT®, the company’s long-acting recombinant factor VIII product for the prevention and treatment of bleeding…

Chris Bombardier has never let severe hemophilia stop him. On January 6, 2018, Chris became the first person with hemophilia – and…

Aptevo Theraoeutics has sold their recombinant factor IX product IXINITY® to Canada-based Medexus Pharmaceuticals. IXINITY®, which first received approval from the U.S….

An important new educational activity has launched for healthcare providers who practice in an emergency department setting. “Evaluation and Management of Hemophilia…